Darunavir:Susc:Pt:Isolate:OrdQn:Phenotyping

Known as: Darunavir:Susc:Pt:Isolato:OrdQn:Fenotipizzazione, Darunavir:Susceptibility:Point in time:Isolate:Quantitative or Ordinal:Phenotyping, Darunaviir:Susc:Pt:Is:OrdQn:Fenotüpiseerimine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
0120082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Darunavir 800 mg once daily (QD) is indicated for HIV-1-infected treatment-naïve and treatment-experienced (without… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needs to be combined… (More)
Is this relevant?
2014
2014
BACKGROUND Cobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure was comparable… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
AIMS ABCB1, some ABCCs and SLCOs have been reported to affect the intracellular accumulation of various protease inhibitors in… (More)
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Data from two Phase IIb trials, POWER 1 and 2 (TMC114-C213 and C202), were pooled to examine the effect of baseline viral… (More)
Is this relevant?